title: The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study.
abstract: The current study aimed to assess the viability of sympathetic sudomotor fibers in cancer patients treated with cisplatin or paclitaxel-based chemotherapy and to ascertain whether this method could contribute to the diagnostic sensitivity of conventional techniques. Sympathetic skin response (SSR) from the hand and sole of 23 cancer patients (nine females and 14 males, mean age 62.4 +/- 10.5 years) was recorded unilaterally before and after chemotherapy with six courses of cumulative cisplatin or paclitaxel containing regimens. Clinical and electrophysiological data were also collected and correlated with the SSR results. Twenty-three healthy subjects served as controls. SSR abnormalities were only present in patients with evidence of peripheral neuropathy assessed by conventional nerve conduction techniques. Three patients had absent SSR in the upper limb whilst six patients had absent SSR both in the upper and lower limbs. In the upper limb, the mean SSR latency was not significantly altered through time (P = 0.086). In the lower limb the mean delay from baseline to follow-up was significantly changed (P = 0.029). In patients, the mean SSR latency was significantly prolonged compared with controls in both upper limb (P = 0.001) and lower limb (P = 0.000). SSR abnormalities were strongly related to sensory conduction abnormalities as detected by conventional techniques (r = 0.39, P = 0.004). Our results showed that SSR does not seem to add to the diagnostic sensitivity of conventional techniques in chemotherapy-induced neuropathy. However, its role in the disclosure of small fibers neuropathy abnormalities is worth considering. Further studies are warranted to address this important issue.
authors.affiliation: Department of Neurology, University of Patras Medical School, Rion, Greece. andargyriou@yahoo.gr
authors.forename: A A
authors.initials: AA
authors.lastname: Argyriou
authors.forename: A
authors.initials: A
authors.lastname: Koutras
authors.forename: P
authors.initials: P
authors.lastname: Polychronopoulos
authors.forename: S
authors.initials: S
authors.lastname: Papapetropoulos
authors.forename: G
authors.initials: G
authors.lastname: Iconomou
authors.forename: G
authors.initials: G
authors.lastname: Katsoulas
authors.forename: T
authors.initials: T
authors.lastname: Makatsoris
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
authors.forename: E
authors.initials: E
authors.lastname: Chroni
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D004558:Electric Stimulation; D004576:Electromyography; D004594:Electrophysiology; D005260:Female; D005712:Galvanic Skin Response; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D017239:Paclitaxel / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012867:Skin / Q000294:innervation* / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D017239:Paclitaxel; D002945:Cisplatin